title: [Scleredema, acanthosis nigricans and IgA/Kappa multiple myeloma].
abstract: BACKGROUND
  Scleredema is an uncommon disease of unknown origin. Characteristic thick skin with symmetrical diffuse induration develops. The infiltration begins on the face and neck then extends to the root of the upper limbs and trunk. There are three clinical types of scleredema. The first is preceded by an upper airway infection and progresses rapidly before regressing spontaneously within a few months. The second type is associated with chronic diabetes. The third type is associated with monoclonal gammapathy, rarely of myelomatous type, and develops insidiously. Acanthosis nigricans can be a paraneoplastic syndrome, often associated with a gastrointestinal cancer. Few cases associating scleredema and acanathosis nigricans have been reported.
  
  
  METHODS
  A 56-year old woman had developed scleredema over the last 6 years when acanthosis nigricans appeared together with IgA kappa multiple myeloma. Treatment with melphalan and prednisolone was effective against the myeloma as well as the scleredema and acanthosis nigricans.
  
  
  CONCLUSIONS
  Only five cases of associated scleredema and multiple myeloma have been reported, four with kappa IgG myeloma and one with IgA myeloma. An association between acanthosis nigricans and sclerederma could be coincidental although the fact that the different manifestations regressed together after the myeloma treatment would suggest some relationship between these three diseases.
authors.affiliation: Service de Médecine, hospital Geral de Santo António, Porto, Portugal.
authors.forename: L
authors.initials: L
authors.lastname: Valente
authors.forename: G C
authors.initials: GC
authors.lastname: Velho
authors.forename: F
authors.initials: F
authors.lastname: Farinha
authors.forename: A
authors.initials: A
authors.lastname: Bernardo
authors.forename: P
authors.initials: P
authors.lastname: Ribeiro
authors.forename: A
authors.initials: A
authors.lastname: Massa
mesh_terms: D000052:Acanthosis Nigricans / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000150:complications* / Q000473:pathology; D005260:Female; D006801:Humans; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D012592:Scleredema Adultorum / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D011239:Prednisolone; D008558:Melphalan